- Home
- AIXI vs APM Comparison
AIXI vs APM Comparison
Compare AIXI & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIXI
- APM
- Stock Information
- Founded
- AIXI 2001
- APM 2010
- Country
- AIXI China
- APM United Kingdom
- Employees
- AIXI N/A
- APM N/A
- Industry
- AIXI Computer Software: Prepackaged Software
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- AIXI Technology
- APM Health Care
- Exchange
- AIXI Nasdaq
- APM Nasdaq
- Market Cap
- AIXI 23.3M
- APM 18.9M
- IPO Year
- AIXI 2023
- APM 2018
- Fundamental
- Price
- AIXI $1.16
- APM $2.09
- Analyst Decision
- AIXI
- APM
- Analyst Count
- AIXI 0
- APM 0
- Target Price
- AIXI N/A
- APM N/A
- AVG Volume (30 Days)
- AIXI 295.7K
- APM 437.5K
- Earning Date
- AIXI 10-27-2025
- APM 04-30-2025
- Dividend Yield
- AIXI N/A
- APM N/A
- EPS Growth
- AIXI N/A
- APM N/A
- EPS
- AIXI N/A
- APM N/A
- Revenue
- AIXI $70,314,315.00
- APM N/A
- Revenue This Year
- AIXI $26.84
- APM N/A
- Revenue Next Year
- AIXI N/A
- APM N/A
- P/E Ratio
- AIXI N/A
- APM N/A
- Revenue Growth
- AIXI 18.84
- APM N/A
- 52 Week Low
- AIXI $1.13
- APM $0.46
- 52 Week High
- AIXI $8.31
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- AIXI 35.22
- APM 54.81
- Support Level
- AIXI $1.15
- APM $1.74
- Resistance Level
- AIXI $1.27
- APM $2.45
- Average True Range (ATR)
- AIXI 0.15
- APM 0.19
- MACD
- AIXI -0.03
- APM 0.04
- Stochastic Oscillator
- AIXI 4.11
- APM 50.63
About AIXI XIAO-I Corporation
XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.